The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Vical has concluded yet again that patients in the phase III trial of Allovectin-7 are living longer than expected, resulting in another lengthy delay before topline data will be released. Naturally, Vical bulls see this as a positive, concluding that it is an indicator that patients are living longer in the treatment arm. That sounds like an old story that I heard earlier this year with Keryx and perifosine, with an unfortunate outcome for the bulls. I believe I've seen similar outcomes from prolonged phase III trials previously, but I can't remember one where the bull thesis turned out to be correct.
I've seen many phase III clinical trials fail against melanoma. It's a bad cancer to bet against and I won't start with Vical.